EPRX
No price yet
Announcements
Nothing here yet
Daily updates
- Eupraxia Pharmaceuticals is evaluating EP-104GI in the placebo-controlled RESOLVE Phase 2b trial for eosinophilic esophagitis, with interim data expected in December 2026. The study is assessing clinical remission and safety after a single local esophageal-wall administration, following Phase 1b/2a results showing a 64% clinical remission rate at Week 52 across multiple cohorts.Oct 4, 2026
- Eupraxia reported long-term Phase 1b/2a RESOLVE results for EP-104GI in eosinophilic esophagitis. Across Cohorts 5–9, 64% of evaluable patients remained in clinical remission at Week 52 after a single injection. The highest-dose cohort maintained a 66% remission rate at 12 months, with marked histological responses and a favorable safety profile, supporting a potential once-yearly maintenance regimen.Oct 1, 2026
FDA designations
Nothing here yet
News
- Eupraxia Pharmaceuticals reaches its enrollment target in the RESOLVE trial evaluating EP-104GI for eosinophilic esophagitisOct 15, 2026
- Eupraxia Pharmaceuticals reports 52-week results from the highest-dose cohort of EP-104GI in the ongoing Phase 1b/2a RESOLVE trial for eosinophilic esophagitisSep 30, 2026
- Eupraxia Pharmaceuticals reported EREFS data from its ongoing RESOLVE trial in eosinophilic esophagitisMay 5, 2026
- Eupraxia reported positive nine-month data from the highest dose cohort in its RESOLVE trial for eosinophilic esophagitisApr 21, 2026
- Eupraxia Pharmaceuticals reported positive tissue data from RESOLVE trial in EoEJan 8, 2026